June 13, 2018
InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world’s leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).
The aim of collaboration is to develop a comprehensive QSP platform of COPD and its treatment including detailed description of immune cell dynamics, effect of cigarette smoke, extracellular matrix remodeling and other aspects of disease progression.
About InSysBio
InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | October 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
1.
01 Oct 2018 12:23
InSysBio Announces Continuation of Collaboration with MedImmune for Quantitative Systems Pharmacology Modeling in Systemic Lupus Erythematosus
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced today an extension of a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for QSP modeling in systemic lupus erythematosus (SLE). The goal is to support the clinical development of anifrolumab, an investigational monoclonal antibody against the type I interferon receptor, by modeling the contributions of key cell types involved in the pathophysiology of lupus that are associated with the type I interferon dysregulation commonly seen with the disease.
|
2
1.
02 Oct 2018 14:05
InSysBio to present at ACoP9
InSysBio announces their participation at Ninth American Conference on Pharmacometrics (ACoP9), to be held October 7th to 10th, 2018, at the Loews Coronado Bay Resort near San Diego, CA. The theme of ACoP9 is “Modeling without Bounds”. InSysBio welcomes visitors at the booth #23.
|
3
|
4
|
5
|
6
|
7
|
|
8
|
9
1.
09 Oct 2018 15:29
InSysBio starts training course “Modeling for systems biology and biomedicine”
InSysBio expert modelers Dr. Galina Lebedeva, Dr. Tatiana Karelina, Dr. Evgeny Metelkin and Dr. Oleg Demin will give the course “Modeling for systems biology and biomedicine” at the Faculty of bioengineering and bioinformatics, Lomonosov Moscow State University.
|
10
|
11
|
12
|
13
|
14
|
|
15
|
16
|
17
|
18
|
19
1.
19 Oct 2018 15:49
InSysBio to present at BiotechClub 2018
InSysBio announces their participation at BiotechClub 2018 conference to be held on October 26th at Hyatt Regency Moscow Petrovsky Park. The theme of BiotechClub 2018 is “From Systems Biology to Systems Medicine”.
|
20
|
21
|
|
22
|
23
|
24
1.
24 Oct 2018 13:49
InSysBio to present at ICSB 2018
InSysBio announces their participation at 19th International Conference on Systems Biology (ICSB 2018) to be held October 28th to November 1st, 2018 in Lyon, France.
|
25
|
26
|
27
|
28
|
|
29
|
30
|
31
| ||||
Thank you for your message! We will get back to you shortly.
